Epidemiology and Survival of Marginal Zone Lymphoma in Colombian Patients: An Observational Retrospective Study.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 40080747.
- Also identified by DOI 10.1200/GO-24-00495.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Marginal zone lymphomas (MZLs) are indolent non-Hodgkin lymphomas, categorized into three subtypes: extranodal, splenic, and nodal MZL (NMZL). MZL epidemiology and outcomes in Latin America remain underexplored. This retrospective cohort study included patients with MZL in Colombia from 2000 to 2023. Patients were followed for at least 24 months from diagnosis. The primary outcomes were real-world overall survival (Rw-OS) and real-world progression-free survival (Rw-PFS). The cohort included 103 patients (63.1% female, 36.9% male) with a median age of 61.8 years. MALT lymphoma was the most common subtype (61.1%), followed by splenic MZL (26.2%) and NMZL (12.7%). The 60-month Rw-OS was 86.4%, and the Rw-PFS was 77.2%. MZL in Colombian patients exhibits varied clinical presentations and survival outcomes. This study underscores the importance of early detection and subtype-specific management of MZL.
Medical subject headings
- Lymphoma, B-Cell, Marginal Zone